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The complete cDNA nucleic acid sequence of preproapolipoprotein (apo) A-II, a major protein constituent 
of high density lipoproteins, has been determined cn clones from a human liver ds-cDNA library. Clones 
containing ds-cDNA for apoA-II were identified in the human liver ds-cDNA library using synthetic oligo- 
nucleotides as probes. Of 3200 clones screened, 4 reacted with the oligonucleotide probes. The DNA se- 
quence coding for amino acids - 17 to + 17 of apoA-II were determined by Maxam-Gilbert sequence analy- 
sis of restriction fragments isolated from one of these clones, pMDB2049. The remainder of the cDNA se- 
quence was established by sequence analysis of a primer extension product synthesized utilizing a restriction 
fragment near the S-end of clone pMDB2049 as primer with total liver mRNA. The apoA-II mRNA en- 
codes for a 100 amino acid protein, preproapoA-II that has an 18 amino acid prepeptide and a 5 amino 
acid propeptide terminating with a basic dipeptide (Arg-Arg) at the cleavage site to mature apoA-II. 
High density lipoprotein Apolipoprotein A-II Oligonucleotide probe Lipoprotein metabolism Nucleic acid 
sequence analysis 
1. INTRODUCTION 
Human apolipoprotein A-II is a major protein 
constituent of HDL. ApoA-II, and the other ma- 
jor protein of HDL, apoA-I, constitute approx. 
90% of the protein moiety of human HDL [ 1,2]. 
HDL has been of particular interest since HDL has 
been inversely associated with the development of 
premature cardiovascular disease [3,4]. Both 
apoA-II as well as apoA-I have been evaluated as 
potential predictors of cardiovascular disease 
]5,61. 
The physiological role of apoA-II in lipoprotein 
metabolism is not as yet clearly defined. Our 
laboratory has previously reported that apoA-II 
activates hepatic lipase in vitro, and may therefore 
play a role in lipolysis of HDL constituents [l I]. 
In man, plasma apoA-II is a 154 amino acid pro- 
tein composed of two identical chains of 77 amino 
acid residues linked by a single disulfide bridge at 
position 6 in the sequence [7]. In nonhuman 
primates [S], and other species [9,10] apoA-II is a 
monomer. 
Human apoA-II is polymorphic in plasma [12]. 
Recently apoA-II has been shown by cell free 
translation to be synthesized as a precursor 
apolipoprotein, preproapoA-II [ 13,141. The par- 
tial amino acid sequence of the prepropeptide has 
been reported by two laboratories. In one report 
the propeptide was 6 amino acids in length with the 
amino acid sequence at the cleavage site similar to 
proapoA-I [ 131, while in the other study proapoA- 
II contains a pentapeptide with cleavage of the 
prosegment after paired basic residues [14]. The 
hepatoma cell line (Hep G2) has been found to 
secrete proapoA-II indicating that conversion to 
the mature protein may occur in plasma [ 141. 
Abbreviations: apo, apolipoprotein; HDL, high density To understand better the biosynthesis and pro- 
lipoproteins; SSC, 1 x SSC is 150 mM NaCl, 15 mM Na cessing of apoA-II, and the potential structural 
citrate and processing defects in patients with dyslipopro- 
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teinemia we have cloned human apoA-II cDNA. 
2, MATERIALS AND METHODS 
2.1. Preparation of a ds-cDNA library of human 
liver mRNA sequences 
RNA was isolated from an adult human liver ob- 
tained from a 34-year-old female accident victim 
(Protocol approved by a Human Research Com- 
mittee) and used to establish a human liver ds- 
cDNA library as detailed in [ lS- 171. All ex- 
periments with bacteria containing recombinant 
plasmids were conducted in accordance with the 
NIH guidelines for recombinant DNA research. 
designed to cover all possible codons of the par- 
ticular amino acid sequence. For hybridization 
each oligonucleotide was radiolabelled at the 
S ’ -OH end group with T4 polynucleotide kinase 
(P-L Biochemicals) and [y-32P]ATP (New England 
Nuclear > 3000 CVmmol). The library was 
screened as in [18], except that the hybridization to 
the oligonucleotides was performed at 32-34°C 
for 40 h. 
2.3, Piasmid preparation 
Plasmids were purified by the cesium chloride 
density gradient procedure [ 191. 
2.2. Screening the library for recombinant 
plasmids containing apoA-II sequences 
Three 14-base-long oligonucleotides deduced 
from the amino acid sequences of residues 13-17, 
20-24 and 26-30 of apoA-II were purchased from 
OCS Labs, Denton, TX. These probes were 
2.4. Restriction enzyme analysis 
Restriction enzymes were purchased from 
Boehringer-Mannheim, Bethesda Research Labor- 
atories, and New England Bio Labs. Digests were 
performed with the conditions specified by the 
suppliers. 
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Fig. 1. Restriction map of pMDB2049. Open bar, inserted ds-cDNA; solid bar, pBR322. The orientation of the coding 
strand within pBR322 is indicated. The asterisks indicate the dG.dC tail. The horizontal arrows indicate the length of 
the sequenced fragments with the arrowheads giving the direction of sequencing. 
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2.5. DNA sequence analysis 
DNA fragments obtained by restriction enzyme 
digestion were labelled either with [a-32P]ddATP 
(> 5000 Ci/mmol, Amersham) using terminal 
transferase (Amersham) [20] or with [Y-~~P]ATP 
using T4 polynucleotide kinase. DNA sequences 
were determined as in [21]. 
2.6. 5 ‘-Extension of cDNA on liver mRNA 
To obtain a suitable primer for cDNA synthesis 
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a restriction fragment of one clone containing the 
5 ’ -end of the insert coding for the NHz-terminal 
region and part of pBR322 was isolated by agarose 
gel electrophoresis, labelled with 32P, and digested 
with PstI. The fragment, which served as the 
primer, was isolated by aqueous acrylamide gel 
electrophoresis, and hybridized to whole liver 
mRNA in 70% formamide at 37°C for 16 h [22]. 
cDNA synthesis was performed as in [16,17]. 
Primer and the extended product were sequenced 
togetl rer. 
70. 
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Fig.2. Maxam-Gilbert DNA sequencing ladders. (A) Sequence of the complementary strand of apoA-II mRNA 
encoding amino acids - 17 to +2. (B) A primer extension. The 70-base-long primer ends at the codon for the Cys in 
position - 10, which is at the bottom of the gel. The extension product at the top is 167 bases long. 
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3. RESULTS 
3.1. Screening for apoA-ZZ ds-cDNA clones 
The human liver ds-cDNA library was screened 
for apoA-II clones with 3 different synthetic 
oligonucleotides (residues 13-17, 20-24 and 
26-30), to maximize specificity because apoA-II 
contains no long amino acid sequences with little 
codon degeneracy. Seven out of 3200 independent 
clones of our ds-cDNA library hybridized to at 
least one of the probes, 4 of which hybridized to all 
3 probes. All clones .were analyzed by restriction 
enzyme digestion. They ranged from 350-1200 
base pairs of insert length. The 4 clones which 
hybridized to all 3 probes were very similar, except 
that they differed in size, thus indicating that they 
were independently derived. The 3 other clones ap- 
peared to be unrelated and were not further 
analysed. 
3.2. ApoA-ZZ cDNA sequence of pMDB2049 
A restriction endonuclease map of pMDB2049 is 
illustrated in fig.1. Based on this map restriction 
fragments were selected which would contain the 
complete nucleotide sequence of this clone. The 
other 3 clones had similar restriction maps except 
that they were shorter in length. The restriction 
fragments used for sequence analysis of the apoA- 
II clone are included in fig.1. pMDB2049 covered 
the protein coding region from amino acid - 17 of 
the preprosequence to amino acid 77 of mature 
apoA-II. Fig.2A illustrates the complementary 
base sequence from amino acid - 17 to + 2. The 
other 3 clones were also sequenced using similar 
strategies. The base sequences common to all 
clones were identical. 
3.3. Complete nucleic acid sequence of human 
liver apoA-ZZ mRNA 
To establish the complete nucleic acid sequence 
we utilized a second approach which employs 
primer extension of a restriction fragment of clon- 
ed apoA-II. pMDB2049 was digested with RsaI 
which generates a blunt end fragment containing 
the 5’-terminal 93 nucleic acids of the coding 
strand, 20 bases of the dG - dC tail, and 239 nucleic 
acids of pBR322. This fragment was isolated, 
labelled at the 5 ’ -OH ends, and cut with PstI. The 
resulting 66/70 base fragment of pMDB2049 was 
hybridized to total liver mRNA, and extended with 
reverse transcriptase. Based on a message level of 
0.2% for apoA-II mRNA [14] the molar ratio of 
primer to apoA-II mRNA was approx. 10: 1. A 
single major 167 base long product was generated 
which indicated that pMDB2049 lacked 74 bases of 
the 5 ’ -end of the apoA-II mRNA. A representative 
sequencing el of a primer extension is illustrated 
in fig.2B. The complete nucleic acid sequence of 
the coding strand for preproapoA-II is shown in 
fig.3. The preproapoA-II mRNA contains a 58 
base-long 5 ’ -untranslated region followed by a 300 
base-long protein coding region and a 
3 ‘-untranslated sequence of at least 72 bases. 
M p- e 
Li’TAGGCCGCCCTCCCCACTGTM3XAC ATG AA0 CT0 CTC GCA GCA ACT GTG CTA CTC CTC ACC ATC TGC AGC CT7 GM GGA GCT TTG GtI COG AGA 
M.4 Lys L.” L.” Ala Ala Thr Val La” L*U Lw Th, Ik CyS S.r LW Wu oly Al8 L.” VN Ars Arg 
-23 -20 -15 -10 -5 -3 
APoA-!l- 
CA0 GCA AAG GAG CCA TOT 010 GAG AGC CTA OTT TCT CA0 TIC TX CA0 ACC GTG ACT GAC TAT GGC AAG GAC CTG AT0 GAG AA0 GTC AAG 
Gin Al8 Lw GIu Pm Cys Val Glu SW Lou “ml SW Gin Tyr Phe Gin Thr Val Thr Aq, Tyr Gly Lys Am,8 Lm, YI 0,” Ly. Vd Lys 
1 6 10 15 20 25 30 
AGC CC* GAG M CAG GCC GAG GCC AA0 TCT TIC TW GM AA0 TCA AAG GAG CA0 CT0 ACA CCC CTG ATC AA0 AAG GCT GGA AC0 GAA CTG 
SW Pm Glu LW Gin Ala Gb Alw Lys SW Tyr PIN Glu Lys SW Lys Glu Gin Lw Thr Pm Lw lb Lys Lys Alm Gly Thr Glu Lw 
3s 40 45 50 55 60 
GTT AAC l-E TTG AGC TAT lTC GTG GM Cll GGA ACA CA0 CCT GCC ACC CA0 TGA AGTGTCCAGACCA~GTCAAccCCAGcTGGcCTCTAGAACAcC 
W Am Ph Lm On Tyr Phn Val Glu Ln, Gly Thr Gin Pm AI. Thr Gin T.m 
65 m 75 
CA~TGG~~AGT~~TAGAG~T~CTGT 3 
Fig.3. ApoA-II cDNA sequence and the derived amino acid sequence of preproapoA-II. The sequence from the 5 ’ -end 
to the codon for amino acid - 12 was established by 5’-extension sequencing. The remainder of the sequence plus an 
overlapping region of 17 bases was determined by sequence analysis of pMDB2049. 
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-23 -20 -10 -5 -1 1 
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Fig.4. Comparison of preproapoA-II and preproapoA-I. 
4. DISCUSSION 
Here we present the complete nucleic acid se- 
quence and the derived amino acid sequence of 
human liver preproapoA-II. PreproapoA-II con- 
tains an 18 amino acid prepeptide and a 5 amino 
acid propeptide connected to the amino-terminus 
of the 77 amino acid mature apoA-II. The derived 
amino acid sequence is in excellent agreement with 
the published protein sequence [lo]. The only dif- 
ference is a glutamic acid in position 37 instead of 
a glutamine. The 5 ‘-untranslated region is most 
probably 58 bases long. This assumption is based 
on the result of the primer extension. The 
3 ’ -untranslated region is at least 72 bases long and 
contains a second stop-codon (TAG) in phase with 
the coding frame. We did not identify the typical 
AATAAA sequence in this region, which is pro- 
bably due to incomplete second strand synthesis. 
Our finding that 4 out of 3200 clones contained 
ds-cDNA for apoA-II is consistent with the 
reported level of liver apoA-II mRNA of 0.2% 
H41. 
Of particular interest in these studies is the com- 
parison of the biosynthesis and processing of 
preproapoA-II and preproapoA-I [16,17,23-251, 
the other major apolipoprotein of HDL. Both 
apolipoproteins are synthesized as preproapolipo- 
proteins. The prepeptides do not show an extensive 
homology (fig.4). The propeptides are strikingly 
different, apoA-II having a pentapeptide termina- 
ting with two basic amino acids, while apoA-I con- 
tains a hexapeptide with a terminal gln-gln dipep- 
tide. ApoA-I is secreted as proform, and is con- 
verted extracellularly to mature apoA-I in vitro 
[26-281, and in vivo in man [29]. The amino acid 
sequence of the cleavage site of proapoA-II, on the 
other hand, is similar to other secretory propro- 
teins which usually undergo effective intracellular 
proteolytic cleavage [30]. The lack of complete 
cleavage of proapoA-II prior to secretion is 
unusual and is as yet unexplained. 
One of the intriguing questions raised by the 
analysis of the biosynthesis and processing of 
apoA-II and apoA-I is the functional role of the 
proproteins. It is as yet unclear if the cleavage of 
the proapolipoprotein to the mature apolipopro- 
tein is associated with the initiation or the termina- 
tion of a specific physiological function. Further 
research will provide new and undoubtedly unex- 
pected insights into the importance of the process- 
ing of these apolipoproteins in lipoprotein 
metabolism. 
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